Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616291 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00616291 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 14 participants.
The verdict
NCT00616291, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of a peptide vaccine in treating patients with metastatic prostate cancer.
Interventions
- BIOLOGICAL NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616291
The ClinicalTrials.gov registry entry for NCT00616291 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine is the first listed.
NCT00616291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00616291 about?
NCT00616291 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer". RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of a peptide vaccine in treating patients with metastatic prostate cancer.
What is the current status of trial NCT00616291?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00616291?
The interventions under investigation include: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00616291?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.